Experiment: 6DO7

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 600
2	2D 1H-13C HSQC aliphatic	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 600
3	2D 1H-13C HSQC aromatic	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 600
4	3D HNCA	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 600
5	3D HNCACB	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 600
7	3D CBCA(CO)NH	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 600
6	3D 15N resolved [1H,1H]-NOESY	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 800
9	3D 13Caliphatic resolved [1H,1H]-NOESY	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 800
8	3D 13Caromatic resolved [1H,1H]-NOESY	20 mM sodium phosphate, 50 mM sodium chloride, 0.5 mM [U-13C; U-15N] Human liver fatty acid binding protein (hFABP1), 90% H2O/10% D2O	90% H2O/10% D2O	20 mM Sodium Phosphate, 50 mM NaCl mM	5.5	1 atm	308	Bruker AVANCE III 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	600
2	Bruker	AVANCE III	800

NMR Refinement
Method	Details	Software
molecular dynamics	the structures are based on a total of 2553 NOE-derived distance constraints, 202 dihedral angle constraints, 58 distance restraints from hydrogen bonds	Prime
Restraint energy minimization	OPALp	OPALp

NMR Ensemble Information
Conformer Selection Criteria	structures with acceptable covalent geometry
Conformers Calculated Total Number	40
Conformers Submitted Total Number	10
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin		Bruker Biospin
2	processing	TopSpin		Bruker Biospin
3	chemical shift assignment	CARA		Keller and Wuthrich
4	peak picking	CARA		Keller and Wuthrich
5	structure calculation	CYANA		Guntert, Mumenthaler and Wuthrich
6	structure calculation	UNIO10-ATNOS/CANID	2.0.2	Dr. Torsten Herrmann
7	refinement	OPALp		Koradi et al, 2000
8	refinement	Prime		Prime, Schrodinger, LLC, New York, NY, 2018

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.